Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

$15 million pledged for creation of Johns Hopkins Greenberg Bladder Cancer Institute

Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife Stephanie Cooper Greenberg have pledged a $15 million gift to create the Johns Hopkins Greenberg Bladder Cancer Institute.

20 May 2014

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Cardiome Pharma Corp. today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets.

20 May 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

Elsevier joins hands with Oncology Nursing Society to review, amend 76 oncology-related skills in Mosby's Skills

Elsevier, a world-leading publisher of scientific, technical and medical information products and services, announced today its collaboration with the Oncology Nursing Society to review and amend 76 oncology-related skills in Mosby's Skills.

20 May 2014

Recruiting more Hispanics to cancer clinical trials crucial to reducing health disparities

Hispanics are the fastest-growing demographic group in the United States, and they suffer from major health disparities, including higher rates of cancers of the cervix, stomach and liver.

20 May 2014

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.

20 May 2014

Norris Cotton Cancer Center receives 3 year term of accreditation from ACR

The American College of Radiology (ACR) has awarded a three-year term of accreditation to Norris Cotton Cancer Center's (NCCC) Radiation Oncology department after a complete review and on-site surveys of its professional and technical practices and facilities in Lebanon, New Hampshire and St. Johnsbury, Vermont.

20 May 2014

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Biovision, the annual forum on future-oriented research in life sciences, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer sessions. Awards will be presented during the closing ceremony.

20 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows.

19 May 2014

University of New Mexico scientist wins prestigious C-Change Comprehensive Cancer Control Champion Award

University of New Mexico Cancer Center scientist Barbara Damron, RN, PhD, FAAN, recently won the prestigious C-Change Comprehensive Cancer Control Champion Award.

19 May 2014

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014.

19 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

New research shows decline in clinical trials handled by CROs

The number of clinical trials started by leading contract research organisations (CROs) dropped by 50% between 2011 and 2013, according to new research from global pharmaceutical analyst firm Datamonitor Healthcare.

16 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014.

16 May 2014

MD Anderson Cancer Center, Concord Medical sign consulting agreement for cancer hospital projects

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company"), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced it has engaged The University of Texas MD Anderson Cancer Center ("MD Anderson") as a consultant for its cancer hospital projects under planning in Shanghai and Beijing.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Lung cancer screening guidelines could cost Medicare billions

A study of Medicare beneficiaries with a history of heavy smoking found that new lung cancer screening guidelines would likely double the proportion of lung cancers found at an early stage, but at a steep cost of more than $9 billion over five years.

16 May 2014

Oncology News and Research

Further Reading

$15 million pledged for creation of Johns Hopkins Greenberg Bladder Cancer Institute

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

BioLineRx announces financial results for Q1 2014, provides operational update

Elsevier joins hands with Oncology Nursing Society to review, amend 76 oncology-related skills in Mosby's Skills

Recruiting more Hispanics to cancer clinical trials crucial to reducing health disparities

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Norris Cotton Cancer Center receives 3 year term of accreditation from ACR

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Vandetanib delays disease progression in elderly NSCLC patients

SUVmax predicts outcome in advanced NSCLC

University of New Mexico scientist wins prestigious C-Change Comprehensive Cancer Control Champion Award

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

New research shows decline in clinical trials handled by CROs

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

MD Anderson Cancer Center, Concord Medical sign consulting agreement for cancer hospital projects

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Lung cancer screening guidelines could cost Medicare billions

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News